Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers

[1]  Kate Owen,et al.  Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2016, eLife.

[2]  I. Ellis,et al.  The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways , 2015, Breast Cancer Research and Treatment.

[3]  Junnian Zheng,et al.  Role of the ERK1/2 pathway in tumor chemoresistance and tumor therapy. , 2015, Bioorganic & medicinal chemistry letters.

[4]  I. Ellis,et al.  Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer , 2014, Breast Cancer Research and Treatment.

[5]  P. Tighe,et al.  A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS) , 2014, European journal of immunology.

[6]  I. Ellis,et al.  Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study , 2014, Breast Cancer Research and Treatment.

[7]  I. Ellis,et al.  SUMOylation proteins in breast cancer , 2014, Breast Cancer Research and Treatment.

[8]  E. Raymond,et al.  MEK in cancer and cancer therapy. , 2014, Pharmacology & therapeutics.

[9]  Jiong Wu,et al.  Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy , 2013, World Journal of Surgical Oncology.

[10]  M. Jiang,et al.  High nuclear phosphorylated extracellular signal-regulated kinase expression associated with poor differentiation, larger tumor size, and an advanced stage of breast cancer. , 2013, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[11]  A. Leroux,et al.  Expression and activation of P38 MAP kinase in invasive ductal breast cancers: correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins. , 2013, Oncology reports.

[12]  K. Jirström,et al.  Low ERK Phosphorylation in Cancer-Associated Fibroblasts Is Associated with Tamoxifen Resistance in Pre-Menopausal Breast Cancer , 2012, PloS one.

[13]  C. Der,et al.  The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery. , 2011, Genes & cancer.

[14]  Stephen L. Abrams,et al.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health , 2011, Oncotarget.

[15]  Heiko A. Mannsperger,et al.  RPPanalyzer: Analysis of reverse-phase protein array data , 2010, Bioinform..

[16]  J. Chambard,et al.  ERK and cell death: Mechanisms of ERK‐induced cell death – apoptosis, autophagy and senescence , 2010, The FEBS journal.

[17]  K. Unsicker,et al.  ERK and cell death: ERK1/2 in neuronal death , 2010, The FEBS journal.

[18]  S. Hilsenbeck,et al.  Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. , 2009, Cancer research.

[19]  G. Emons,et al.  GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax. , 2009, Cancer research.

[20]  Y. Tesfaigzi,et al.  How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? , 2009, Cell cycle.

[21]  F. Jänicke,et al.  Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary carcinomas. , 2009, Anticancer research.

[22]  T. Ikejima,et al.  Protein tyrosine kinase, JNK, and ERK involvement in pseudolaric acid B-induced apoptosis of human breast cancer MCF-7 cells , 2008, Acta Pharmacologica Sinica.

[23]  Z. Ronai,et al.  ATF2: A transcription factor that elicits oncogenic or tumor suppressor activities , 2008, Cell cycle.

[24]  J. Licht,et al.  ATF-2 controls transcription of Maspin and GADD45α genes independently from p53 to suppress mammary tumors , 2008, Oncogene.

[25]  I. Ellis,et al.  Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. , 2008, European journal of cancer.

[26]  J. Ramos.  The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. , 2008, The international journal of biochemistry & cell biology.

[27]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.

[28]  U. Rapp,et al.  Ras oncogenes and their downstream targets. , 2007, Biochimica et biophysica acta.

[29]  O. Rath,et al.  MAP kinase signalling pathways in cancer , 2007, Oncogene.

[30]  Goberdhan P Dimri,et al.  Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior. , 2007, Cancer research.

[31]  Ian O Ellis,et al.  Prognostic markers in triple‐negative breast cancer , 2007, Cancer.

[32]  S. Altiok,et al.  JNK pathway regulates estradiol-induced apoptosis in hormone-dependent human breast cancer cells , 2007, Breast Cancer Research and Treatment.

[33]  Douglas Macmillan,et al.  Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. , 2006, European journal of cancer.

[34]  C. Johannessen,et al.  A negative feedback signaling network underlies oncogene-induced senescence. , 2006, Cancer cell.

[35]  A. Chinnaiyan,et al.  Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. , 2006, Cancer research.

[36]  A. Chinnaiyan,et al.  Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. , 2006, Cancer research.

[37]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[38]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[39]  M. Cherian,et al.  Inhibition of extracellular signal regulated kinase (ERK) leads to apoptosis inducing factor (AIF) mediated apoptosis in epithelial breast cancer cells: The lack of effect of ERK in p53 mediated copper induced apoptosis , 2005, Journal of cellular biochemistry.

[40]  T. Löning,et al.  Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer , 2005, British Journal of Cancer.

[41]  M. Karin,et al.  From JNK to Pay Dirt: Jun Kinases, their Biochemistry, Physiology and Clinical Importance , 2005, IUBMB life.

[42]  Chun-ching Lin,et al.  Asiatic Acid, a Triterpene, Induces Apoptosis and Cell Cycle Arrest through Activation of Extracellular Signal-Regulated Kinase and p38 Mitogen-Activated Protein Kinase Pathways in Human Breast Cancer Cells , 2005, Journal of Pharmacology and Experimental Therapeutics.

[43]  Anita B. Roberts,et al.  Role of Rho/ROCK and p38 MAP Kinase Pathways in Transforming Growth Factor-β-mediated Smad-dependent Growth Inhibition of Human Breast Carcinoma Cells in Vivo* , 2004, Journal of Biological Chemistry.

[44]  D. Rimm,et al.  X-Tile , 2004, Clinical Cancer Research.

[45]  I. Ellis,et al.  Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma , 2004, British Journal of Cancer.

[46]  A. Paradiso,et al.  Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  C. Mamay,et al.  An inhibitory function for JNK in the regulation of IGF-I signaling in breast cancer , 2003, Oncogene.

[48]  C. Weston,et al.  The JNK signal transduction pathway. , 2007, Current opinion in genetics & development.

[49]  V. Keshamouni,et al.  MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance , 2002, Oncogene.

[50]  F. Kern,et al.  Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells , 2001 .

[51]  Serge Lemay,et al.  The p38 MAPK Pathway Is Required for Cell Growth Inhibition of Human Breast Cancer Cells in Response to Activin* , 2001, The Journal of Biological Chemistry.

[52]  J. Avruch,et al.  Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. , 2001, Physiological reviews.

[53]  F. Kern,et al.  Hyperactivation of MAPK Induces Loss of ER a Expression in Breast Cancer Cells , 2001 .

[54]  K. Reddy,et al.  Mitogen‐activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP‐9) in breast epithelial cells , 1999, International journal of cancer.

[55]  H. Schaeffer,et al.  Mitogen-Activated Protein Kinases: Specific Messages from Ubiquitous Messengers , 1999, Molecular and Cellular Biology.